In ovarian cancer, cisplatin induces CAF-derived CCL5 secretion, promoting drug resistance, mediated by PI3K and STAT3 signaling pathway regulation, inhibiting apoptosis and promoting proliferation (92). Here, CCL5 is linked to ovarian cancer.